Cevec signs exclusive license to develop HCMV vaccine
This article was originally published in Scrip
Executive Summary
German biotechnology firm Cevec Pharmaceuticals has signed an exclusive license agreement for the development of Vakzine Projekt Management's (VMP) novel human cytomegalovirus (HCMV) dense body technology.